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A 3 Enhancer in the IL-4 Gene Regulates Cytokine
Production by Th2 Cells and Mast Cells
lineages of the immune system, respectively (Mekori
and Metcalfe, 2000; Mosmann and Coffman, 1989). The
process of Th2 differentiation has been extensively stud-
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ied due to the ease with which naive CD4 T cell precur-1The Department of Pathology and
sors can be isolated from mice and differentiated ex2 The Department of Genetics
vivo (Mosmann et al., 1986). In naive T cells, signalingHarvard Medical School
through the IL-4 receptor in the presence of antigen3 The Center for Blood Research
stimulation leads to activation of the transcription fac-4 Howard Hughes Medical Institute and
tors STAT6 and GATA-3, which are essential for estab-Children’s Hospital
lishment of the Th2 differentiation program (Kaplan etBoston, Massachusetts 02115
al., 1996; Takeda et al., 1996; Zheng and Flavell, 1997;
Zhang et al., 1999). Another IL-4/STAT6-induced tran-
scription factor, c-Maf, is important for the inducibleSummary
expression of the IL-4 gene in already differentiated Th2
cells (Kim et al., 1999). In contrast, early differentiationDifferentiation of naive T cells into mature Th2 cells
of murine mast cells occurs in the bone marrow andis associated with the appearance of a complex pat-
requires an entirely different set of stimuli, IL-3 and SCFtern of DNase I hypersensitive (DH) sites within the
(stem cell factor, the c-Kit ligand) (Galli and Hammel,IL-4/IL-13 cytokine gene cluster. We show here that
1994). Early mast cells leave the bone marrow, entertargeted deletion of an inducible DH site, VA, and the
their destination tissue (e.g. skin, gastrointestinal mu-adjacent conserved DH site V (CNS-2) selectively com-
cosa, respiratory mucosa), and complete their differenti-promises IL-4 gene transcription by differentiated Th2
ation under the influence of local environmental factorscells and mast cells. In mast cells, the deletion abro-
(Kitamura, 1989). Because of the difficulty in identifyinggates IL-4 mRNA induction, an effect mimicked by
and isolating large numbers of mast cell precursors, itdeletion of the transcription factor NFAT1 (NFATc2),
is not yet possible to reconstitute mast cell differentia-which binds DH site VA. In T cells, the deletion impairs
tion ex vivo. However by culturing whole bone marrowa process of response maturation, defined by progres-
with IL-3, it is possible to obtain cells that resemblesive increases in IL-4 levels as Th2 differentiation pro-
early mast cells before they enter the tissues (Galli etceeds. These results identify an essential enhancer
al., 1982). When injected into mice, these bone marrow-which regulates IL-4 gene expression in two important
derived mast cells (BMMCs) home to tissues and com-cell lineages in vivo.
plete their differentiation (Nakano et al., 1985). BMMCs
are capable of producing IL-4 and IL-13 yet do not ex-Introduction
press the transcription factors vital for IL-4 and IL-13
production in Th2 cells, STAT6, and GATA-3 (ShermanThe production of cytokines by the immune system is
et al., 1999b; Zon et al., 1991). c-Maf is also not requiredcritical for determining the outcome of an immune re-
for mast cell transcription of the IL-4 gene (Sherman etsponse. Of particular importance are the Th2 cytokines
al., 1999a).IL-4, IL-5, and IL-13, which are crucial for immunity
Several laboratories have investigated regulation ofagainst extracellular pathogens and helminth parasites
IL-4, IL-5, and IL-13 production by Th2 cells (reviewed inbut also contribute to the pathology of allergy, asthma,
Glimcher and Murphy, 2000; Murphy et al., 2000; O’Garra
and other atopic diseases (Romagnani, 1994; Sher and
and Arai, 2000). These cytokines are all encoded within a
Coffman, 1992). IL-5 promotes eosinophil differentiation
cytokine gene cluster that spans200 kb and is strongly
(Wardlaw et al., 1995) while a fundamental function of conserved among mammalian species (Frazer et al.,
IL-4 is to drive the differentiation of naive T cells into 1997; Loots et al., 2000). Th2 differentiation correlates
Th2 cells which are then capable of transcribing the with development of a complex pattern of DNase I hy-
IL-4, IL-5, and IL-13 genes (Seder et al., 1992; O’Garra, persensitive (DH) sites on the IL-4/IL-13 locus (Agarwal
1998). IL-4 and IL-13 have multiple roles, among which and Rao, 1998; reviewed in Avni and Rao, 2000; Take-
is the ability to promote B cell class switching to IgE moto et al., 1998) (see Figure 1A). Several of the DH
(Brown and Hural, 1997; Zurawski and de Vries, 1994). sites correspond to conserved regions which show high
IgE, bound by high affinity Fc receptors on the surface sequence identity (80%) when different mammalian
of mast cells, basophils, and eosinophils, causes de- species are compared (Loots et al., 2000; Lee et al.,
granulation and production of inflammatory mediators 2001). One of these, conserved noncoding sequence
and cytokines when crosslinked by antigen (Galli, 1993). (CNS)-1, is located in the intergenic region between IL-
Subsequent production of IL-4 and IL-13 by mast cells 13 and IL-4 and overlaps two Th2-specific DH sites,
locally may prolong Th2 responses. HSS1 and HSS2 (Loots et al., 2000; Takemoto et al.,
Mast cells and Th2 cells express both IL-4 and IL-13, 1998). Deletion of CNS-1 in the context of a human YAC
despite having developed from the myeloid and lymphoid transgene or the endogenous mouse locus resulted in
significant (2- to 4-fold) decreases in production of IL-4,
IL-5, and IL-13, suggesting a global role for this se-5 Correspondence: arao@cbr.med.harvard.edu
6 These authors contributed equally to this work. quence in transcription of these linked cytokine genes
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(Loots et al., 2000; Mohrs et al., 2001). A second con-
served noncoding sequence, CNS-2, is contained within
DH site V, a Th2-specific DH site located 3 of the IL-4
gene that is constitutively present in both resting and
stimulated Th2 cells (Agarwal and Rao, 1998). Adjacent
to DH site V is an inducible DH site, VA, which is apparent
only in stimulated Th2 cells; it binds the Th2-specific
transcription factor GATA-3 and the inducible transcrip-
tion factor NFAT1 (NFATp, NFATc2) in chromatin immu-
noprecipitation experiments and functions as an induc-
ible, Th2-specific enhancer in transient reporter assays
(Agarwal et al., 2000).
Work on mast cell cytokine transcription has focused
mainly on IL-4 gene expression. Early studies suggested
that the transcription factor complexes binding to cis
elements in the IL-4 promoter differed from those ob-
served in Th2 cells (Brown and Hural, 1997). A region
within the second intron acts as an enhancer of IL-4
transcription in transfected mast cell lines (Henkel et al.,
1992). It has been shown to bind GATA-1, GATA-2, and
PU.1, factors specific to mast cells (Henkel and Brown,
1994). There is also evidence that this region helps main-
tain the demethylated status and accessibility of the
IL-4 locus in mast cells (Hural et al., 2000). Transformed
mast cell lines show DNase I hypersensitivity patterns
on the IL-4/IL-13 locus that are similar to those observed
in Th2 cells (Agarwal and Rao, 1998). However, deletion
of CNS-1 had no effect on cytokine expression by pri-
mary mast cells (Mohrs et al., 2001), suggesting that T
cells and mast cells might utilize different regulatory
regions to modulate IL-4 and IL-13 gene expression.
In this study we compare the regulation of IL-4 and
IL-13 expression in primary mast cells and Th2 cells. Figure 1. DNase I Hypersensitivity Pattern of the IL-4 Gene in Mast
CellsWe show that these two cell types develop similar but
(A) Diagram of the IL-4/IL-13 locus showing the locations of thenot identical patterns of DNase I hypersensitivity on the
DNase I hypersensitive clusters (vertical arrows) and the conservedIL-4 gene. Targeted deletion of two adjacent DH sites,
CNS-1 and CNS-2 regions (ovals). The IL-4 and IL-13 genes and thethe constitutive DH site V and the inducible DH site VA, last exon of the KIF3A gene are shown as black boxes.
results in a profound decrease in IL-4 expression by (B) DNase I hypersensitivity pattern of unstimulated ( stim.) BMMC
mast cells as well as Th2 cells, suggesting that these using the 5 IL-4 probe.
two cell types utilize similar underlying mechanisms to (C) DNase I hypersensitivity pattern of unstimulated ( stim.) and
stimulated ( stim.) BMMC using the 3 IL-4 probe.regulate IL-4 gene transcription.
(D) Diagram of the 19 kb BamHI (B) fragment containing the IL-4
locus. Exons are shown as black boxes and DNase I hypersensitive
Results sites as vertical arrows. The 5 and 3 probes are indicated by black
bars.
Similar Patterns of DNase I Hypersensitivity in Mast
Cells and Th2 Cells
We first asked whether mast cells and Th2 cells devel- 1998), as well as DH sites in the IL-13 gene (data not
shown). These results are interesting since BMMC differ-oped the same pattern of DNase I hypersensitivity on
the IL-4 gene. We generated BMMCs from wild-type entiate in response to stimuli different from that to which
Th2 cells respond. IL-4 and IL-13 expression by BMMCmice ex vivo by culturing bone marrow precursors with
IL-3-containing conditioned medium for 4–6 weeks. The does not require the Th2 transcription factors STAT6 or
c-Maf (Sherman et al., 1999a, 1999b; also see Supple-DNase I hypersensitivity pattern of the IL-4 gene in the
differentiated mast cells was almost identical to that mental Figures S1A and S1B at http://www.immunity.
com/cgi/content/full/17/1/41/DC1); moreover, BMMC doobserved in Th2 cells (Figure 1B; Agarwal and Rao,
1998), with the exception that site VA, an inducible DH not express GATA-3 RNA (Zon et al., 1991) or protein
(see Supplemental Figure S1C at http://www.immunity.site in Th2 cells, was weakly apparent in mast cells under
resting conditions (Figure 1C, lanes 2–5). Nevertheless, com/cgi/content/full/17/1/41/DC1).
the site still behaved as an inducible DH site, since its
intensity increased upon stimulation (Figure 1C, lanes Deletion of Hypersensitive Sites V and VA
from the Endogenous IL-4 Gene7–10), and this increase was sensitive to cyclosporin A
(CsA) (data not shown). Additional experiments con- In addition to the inducible DH site VA, the 3 region of
the IL-4 gene contains two constitutive DH sites, site IVfirmed that mast cells possessed the intergenic DH site,
HSS3, observed in the IL-4/IL-13 locus (Takemoto et al., and site V (Figures 1A and 1C). DH site V contains CNS-2
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Figure 2. Targeted Deletion of DH Sites V and VA in the IL-4 Gene
(A) Diagram of the 3 region of the IL-4 locus, the targeting construct used for the site V/VA deletion, and the IL-4 locus after Cre-mediated
deletion of the PGK-neor selection cassette. Exon (ex) 4 of the IL-4 gene and the last exon of the KIF3A gene are indicated by black boxes.
DH sites IV, V, and VA, the conserved noncoding sequence (CNS-2) present within DH site V, and the 5 and 3 probes used for Southern
analysis are indicated. Restriction enzyme sites (B, BamHI; H, HindIII; A, AvrII) and loxP sites are shown.
(B) Southern analysis of BamHI-digested DNA from targeted ES cells before and after Cre-mediated deletion of the neor cassette. The wild-
type IL-4 locus is contained within a 19 kb BamHI fragment; replacement of the 3.7 kb region including site V and site VA with the neor cassette
(Neo) yielded BamHI fragments of 13.0 and 4.7 kb when screened with the 5 and 3 probes, respectively. Cre-mediated deletion of the neor
cassette (Del) removed the introduced BamHI site, yielding a BamHI fragment of 15.3 kb with both 5 and 3 probes. Only one IL-4 allele was
targeted; hence, the 19kb BamHI fragment from the wild-type allele is observed in all lanes.
(C) Deletion of DH sites V and VA does not affect formation of other DH sites or induce the appearance of new DH sites in the IL-4 gene. Wild-
type (WT) and V/VA KO (V/VA) Th2 cells were differentiated ex vivo from CD4 T cells. After 3 weeks of differentiation, cells were stimulated
with PMA and ionomycin for 4 hr. DNase I hypersensitivity analysis was performed on isolated nuclei using the 5 probe. Site III, normally a
faint DH site, is not visible in this exposure. The 19 kb BamHI parental fragment in the wild-type cells becomes smaller (15.3 kb) when the
V/VA region is deleted and therefore migrates at a slightly faster rate in the gel. Identical results were obtained with wild-type and V/VA KO
mast cells.
while site IV, upstream from sites V and VA, is not Th2 4-week-old V/VA KO mice and differentiated under Th2
conditions for three weeks developed a normal DNasespecific and is seen in both naive T cells and Th1 cells
(Agarwal and Rao, 1998). We deleted the adjacent DH I hypersensitivity pattern at other regions of the IL-4
gene (Figure 2C), as did BMMC differentiated for 8sites V and VA and, separately, DH site IV from the endog-
enous IL-4 gene. Here we focus on the effects of deleting weeks from the bone marrow of 4-week-old V/VA KO
mice (data not shown). These results indicate that DHDH sites V and VA; the effects of the site IV deletion will
be reported elsewhere. Targeted disruption of DH sites sites V and VA are not necessary to establish the charac-
teristic complex pattern of DNase I hypersensitivity onV and VA was performed by deleting a 3.7 kb fragment
containing sites V and VA from the IL-4 gene by homolo- the IL-4 gene in either Th2 cells or mast cells.
gous recombination in ES cells (Figure 2A). The intro-
duced PGK-neor cassette, which had been flanked with The V/VA Deletion Almost Completely Abrogates IL-4
Expression by Mast CellsloxP sites, was then removed by transfection with the
Cre recombinase (Figures 2A and 2B). The V/VA-deleted Comparison of wild-type and V/VA KO mast cells showed
that the V/VA region was critical for IL-4 production byES cells were injected into C57BL/6 blastocysts, and mice
homozygous for the V/VA deletion (designated V/VA KO mast cells. Mast cells from V/VA KO mice displayed an
almost complete loss of the ability to induce IL-4 mRNAmice) were generated. CD4 T cells isolated from 3- to
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Figure 3. The V/VA Region Is Essential for IL-4
Transcription by Mast Cells
(A) RNase protection assay (RPA) to compare
cytokine expression by wild-type (WT) and
V/VA KO (V/VA) BMMC. Cells were stimulated
over a period of 4 hr. RNA was isolated at the
time points indicated and subjected to RPA
analysis with the mCK-1b template set. The
upper and lower panels were exposed for 5
and 1 hr, respectively.
(B) Quantification of IL-4 and IL-13 transcript
levels from two independent experiments, in-
dicated by circles and triangles, respectively.
Triangles show data from the experiment in
(A). Transcript levels at each time point were
quantified, and the maximum intensity for
each experiment was set at 100%. The other
data points were plotted relative to the maxi-
mum. The lines show average values at each
time point. Solid lines and filled symbols,
wild-type BMMC; dashed lines and open
symbols, V/VA KO BMMC.
(C) Equivalent surface expression of c-Kit and
FcRI on wild-type and V/VA KO BMMC. Cells
were stained for FcRI and c-Kit as described
in the Experimental Procedures. Thick lines,
FcRI- or c-Kit-positive staining; thin lines,
background controls.
(Figures 3A and 3B). We also observed a decrease of marked decrease in levels of IL-13 and TNF- tran-
scripts (Figures 4A–4C). This effect could not be attrib-IL-13 transcript levels, but the magnitude of this effect
was lower and more variable between experiments (two uted to failure of mast cells to express other NFAT pro-
teins; expression of NFAT2 and NFAT4 was equivalentindependent experiments are represented by circles
and triangles in Figure 3B). Decreased cytokine expres- in wild-type and NFAT1-deficient mast cells (Figure 4D).
NFAT1/ BMMCs and wild-type BMMCs expressedsion in the V/VA KO mast cells was not due to reduced
surface expression of the high affinity IgE receptor, comparable levels of FcRI and c-Kit (Figure 4E), ruling
out defects in development or initial signaling responsesFcRI, through which the mast cells were stimulated or
to a failure of mast cell differentiation as judged by to crosslinked IgE. However, the strong dependence of
mast cell cytokine production on NFAT1 was unex-surface expression of c-Kit, the receptor for SCF (Figure
3C). Thus, the major effect of the V/VA deletion in mast pected, since Th2 cells lacking NFAT1 show no de-
crease but rather a mild increase in Th2 cytokine produc-cells was to disrupt IL-4 gene transcription, with a
smaller and more variable effect on transcription of the tion (Hodge et al., 1996; Kiani et al., 1997; Xanthoudakis
et al., 1996).linked IL-13 gene.
NFAT1 Deletion Mimics the Effect of the V/VA Deletion The V/VA Deletion Greatly Diminishes IL-4 Expression
by Differentiated Th2 Cellson IL-4 Expression by Mast Cells
Since the site VA enhancer is known to bind NFAT1 We evaluated the role of the V/VA region in Th2 cytokine
expression, using CD4 T cells differentiated under Th2(Agarwal et al., 2000), we examined cytokine production
by mast cells from NFAT1-deficient mice (Xanthoudakis conditions for 1 to 8 weeks (Figures 5 and 6). For the
experiments in Figure 5, Th2 cells were restimulated foret al., 1996). NFAT1/ mast cells showed no change in
the pattern of DNase I hypersensitivity developing on different times, after which total RNA was isolated and
analyzed by RNase protection assay (RPA). After 1 weekthe IL-4 gene (data not shown), indicating that NFAT1
is not required for remodeling of the IL-4 locus during of differentiation, V/VA KO Th2 cells were clearly able to
transcribe the IL-4 gene when restimulated with anti-BMMC differentiation. However, they showed an almost
complete loss of IL-4 transcript induction, as well as a CD3/anti-CD28 or the stronger stimulus, PMA/iono-
IL-4 Regulation in Th2 Cells and Mast Cells
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Figure 4. NFAT1-Dependent Transcription of Cytokine Genes in Mast Cells
(A and B) RPA analysis of wild-type (WT) and NFAT1-deficient (NFAT1/) BMMC stimulated over the course of 3 hr. The mCK-1 (A) and
mCK-3 (B) template sets were used. The IL-4 panels in (A) were exposed for 18 hr while all other panels were exposed for 1 hr.
(C) Quantification of RPA results from (A) and (B). Open symbols, NFAT1/ BMMC; filled symbols, WT BMMC.
(D) Equivalent expression of NFAT2 and NFAT4 in NFAT1/ mast cells. Whole-cell extracts were prepared from wild-type and NFAT1-deficient
BMMC and pretreated with cyclosporin A to prevent NFAT dephosphorylation during cell lysis. Proteins were separated on a 7% polyacrylamide
gel and analyzed by Western blotting to detect NFAT1, NFAT2, and NFAT4 (panels 1, 2, and 3, respectively). Arrowheads mark the positions
of NFAT proteins. Minor dephosphorylation of NFAT4 is observed in the NFAT4/ lysates in panel 3. The specificity of the antibodies was
confirmed by Western blot of extracts from HEK cells transfected with recombinant NFAT proteins (data not shown).
(E) Equivalent surface expression of c-Kit and FcRI on wild-type and NFAT1-deficient BMMC. For details, see legend to Figure 3C.
mycin; however, the levels of IL-4 transcripts produced We also examined IL-4 production at the single-cell
level by intracellular cytokine staining of wild-type andwere consistently lower than observed for wild-type Th2
cells (Figure 5B, lanes 1–6, and Figure 5A, lanes 1–14). V/VA KO Th2 cells (Figure 6B). Cells from independent
cultures (corresponding to Experiments Two and ThreeIn five independent experiments, V/VA KO Th2 cells
showed 1.3- to 5-fold lower levels of IL-4 transcripts of Figure 6A) were stimulated with PMA/ionomycin after
1 or 8 weeks of differentiation under Th2 conditions. Inrelative to wild-type Th2 cells after 1 week of Th2 differ-
entiation (mean  3.3  1.6). The IL-4 transcription de- both cases, the fraction of V/VA KO Th2 cells that stained
positive for intracellular IL-4 was approximately 4- tofect was maintained or became more pronounced as
Th2 differentiation progressed (Figures 5A and 5B; 5-fold lower than the corresponding fraction of IL-4-
positive wild-type Th2 cells (Figure 6B). Cells from thesequantified in graphs at right). The V/VA deletion also had
a detectable but variable effect on transcription of the cultures were also stained for intracellular IL-4 after
stimulation with anti-CD3/anti-CD28; although the frac-linked IL-5 and IL-13 genes by Th2 cells, with no effect
on transcription of the unlinked gene IL-10 (Figures 5A tion of IL-4 positive cells was lower, the 4- to 5-fold
difference between wild-type and knockout V/VA KO Th2and 5B; see quantification in accompanying graphs).
The experiments in Figure 5 measure steady-state cells was maintained (data not shown). Thus, the site
V/VA region acts as a strong IL-4 enhancer in Th2 cellstranscript levels that reflect both synthesis and degrada-
tion of cytokine mRNAs. We therefore examined the and deletion of the region results in a substantial de-
crease in the amount of IL-4 produced per cell. Sinceeffect of the V/VA deletion on cytokine accumulation by
ELISA (Figure 6A). This assay confirmed the consistent intracellular staining probably detects only the cells ex-
pressing the highest levels of IL-4, this decrease is alsodefect in IL-4 expression by V/VA KO Th2 cells, as well
as the more variable nature of the defect in IL-5 and apparent as a decrease in the frequency of IL-4-produc-
ing Th2 cells in the population.IL-13 expression. The decrease in IL-4 production was
10- to 12-fold in experiment two and 7- to 17-fold in
experiment three (compare black and white bars in Fig- The V/VA Region Does Not Act as a Boundary Element
for the IL-4 Geneure 6A). In contrast, levels of IL-5 and IL-13 showed a
substantial decrease in experiment two, (IL-5, 4- to The V/VA region is located 3 of the IL-4 gene in a location
appropriate for a boundary element between the IL-48-fold; IL-13, 3- to 5-fold), but little or no change in
experiment three. IL-10 levels were equivalent in wild- and KIF3A genes (Figure 1A). KIF3A expression is ubiq-
uitous but occurs predominantly in the central nervoustype and V/VA KO Th2 cells in both experiments, a finding
that mirrors the results of the RNA analysis in Figure 4. system (Kondo et al., 1994). RT-PCR analysis showed
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Figure 5. The V/VA Region Regulates IL-4 Transcription by Th2 Cells
Wild-type (WT) and V/VA KO (V/VA) Th2 cells, differentiated for 1, 2, or 3 weeks ex vivo as indicated, were stimulated over the course of 8 hr
(A) or 4 hr (B). Cytokine transcript levels were monitored by RPA using the mCK-1b (A) or mCK-1 (B) templates. Levels of cytokine transcripts
were quantified and plotted to the right of each autoradiograph after normalization of the cytokine bands to the L32 standards in each lane.
Open symbols, V/VA KO Th2 cells; filled symbols, wild-type Th2 cells.
(A) Response to PMA/ionomycin stimulation.
(B) Response to anti-CD3/anti-CD28 (-CD3/-CD28) stimulation.
that KIF3A is expressed in both Th1 and Th2 cells but Th2 cells show increased expression of IL-4 mRNA, es-
not in mast cells; the V/VA deletion neither decreased pecially at late time points after stimulation (Hodge et
KIF3A expression in Th1 cells and Th2 cells nor induced al., 1996; Kiani et al., 1997). In both NFAT1-deficient cell
KIF3A expression in mast cells (data not shown). types, there is no change in expression of NFAT2 and
NFAT4, and induction of DH site VA occurs normally (S.A.
and D.C.S., unpublished data), implying that other NFATDiscussion
proteins can bind this enhancer region following stimula-
tion. In T cells, binding of either NFAT1 or NFAT2 leadsEffects on Mast Cells
to productive IL-4 transcription: IL-4 production is abro-We show here that deletion of a region containing a
gated only when both proteins are absent (Peng et al.,highly conserved noncoding sequence, CNS-2, and an
2001), and both constitutively active proteins positivelyinducible IL-4 enhancer, DH site VA, impairs transcription
regulate IL-4 expression in retrovirally infected Th2 cellsof the IL-4 gene in both mast cells and Th2 cells. In
(S. Monticelli and A.R., unpublished data). However, incontrast, deletion of the transcription factor NFAT1,
mast cells our results suggest that NFAT1 is primarilywhich binds site VA, has different effects in mast cells
responsible for IL-4 gene transcription. A plausible hy-and Th2 cells. NFAT1-deficient mast cells show de-
creased IL-4 expression (this report), whereas NFAT1/ pothesis to explain these data is that in Th2 cells, NFAT1
IL-4 Regulation in Th2 Cells and Mast Cells
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Figure 6. The V/VA Region Is Essential for IL-4 Protein Production by Th2 Cells
(A) ELISA analysis. Two sets of wild-type (WT) and V/VA KO (V/VA) CD4 T cell cultures, designated “Expt. 2” and “Expt. 3,” were differentiated
over the course of 3 weeks. At the end of each week, each culture was stimulated for 4 hr with PMA and ionomycin, and cell supernatants
were collected and assayed for IL-4, IL-5, IL-13, and IL-10 cytokines. Experiment two corresponds to the same culture and stimulation as
experiment two of Figure 5B; cells were lysed for RNA immediately after supernatants had been collected. Experiment three is a separate
set of cultures. Unstimulated cells produced no detectable cytokines.
(B) Intracellular cytokine staining for IL-4. Wild-type and V/VA KO CD4 T cells were differentiated for 1 week (top four panels) or 8 weeks
(bottom four panels) under Th2 conditions, then either left unstimulated (thin lines) or treated with PMA and ionomycin (thick lines) for 4 or 6
hr, as indicated. The percentage of cells expressing IL-4 (numbers in upper right corner of each graph) was analyzed by flow cytometry.
and NFAT2 cooperate equivalently with GATA-3 at the proteins (Weiss and Orkin, 1995). It therefore seems
likely, as previous work suggests (Weiss and Brown,site VA enhancer while in mast cells, NFAT1 interacts
preferentially with GATA-1 and GATA-2. Alternatively, 2001), that the similar DNase I hypersensitivity patterns
in Th2 cells and mast cells reflect the participation ofNFAT1 and NFAT2 may interact similarly with T cell
coactivator proteins but differentially with mast cell- related STAT and GATA transcription factors in these
two cell types.specific coactivators. We are currently testing these
hypotheses.
The DNase I hypersensitivity pattern developing on
the IL-4 gene was very similar in primary mast cells and Effects on Th2 Cells
We have shown that the IL-4 expression defect of theTh2 cells. This similarity was unexpected since these
two cell types differentiate in response to different stim- V/VA KO Th2 cells becomes more apparent as Th2 differ-
entiation progresses. As depicted in Figure 5, wild-typeuli which utilize unrelated signal transduction pathways;
moreover, STAT6 and GATA-3, which are essential for Th2 cells show increased induction of IL-4, IL-5, IL-13,
and IL-10 cytokine mRNAs with increasing times of Th2Th2 differentiation, do not play a role in mast cell cyto-
kine production (Sherman et al., 1999b; Zon et al., 1991; differentiation. This phenomenon, which we provision-
ally refer to as “Th2 maturation,” likely reflects both ansee Supplemental Figure S1 at http:www.immunity/
com/cgi/content/full/17/1/41/DC1). Mast cell differenti- increased number of cytokine-expressing cells in the
population as well as an increased level of cytokineation induced by IL-3 is likely to involve the STAT family
member STAT5 (Hural et al., 2000), which has a DNA expression per cell (Figure 6B). While we observed some
variation in the extent to which IL-4 expression wasbinding specificity similar to that of STAT6 and other
STAT family proteins (Xu et al., 1996); similarly, although impaired in V/VA KO Th2 cells at week 1, there was
always a striking difference at later weeks (Figures 5mast cells do not express GATA-3, they express GATA-
1 and GATA-2 (Martin et al., 1990; Zon et al., 1991) and 6). Thus, the process of Th2 maturation is impaired
in site V/VA KO Th2 cells, in that even cells differentiatedwhich bind to DNA with similar selectivity as other GATA
Immunity
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for 8 weeks do not express the levels of cytokine ob- redundant functions, a combined CNS-1/CNS-2 deletion
served in wild-type Th2 cells (Figure 6B). might have major effects on transcription of the entire
The site V/CNS-2 region is unusual in that it is demeth- IL-4/IL-5/IL-13 cytokine cluster in mast cells as well as
ylated in naive T cells prior to antigen encounter; almost Th2 cells.
all other tested regions of the IL-4/IL-13 locus are
Experimental Proceduresstrongly methylated in naive T cells and become gradu-
ally demethylated during the course of Th2 differentia-
Animals
tion in a manner that correlates with high-level IL-4 ex- All mice were maintained in pathogen-free conditions in barrier facili-
pression (Lee et al., 2002). This might suggest that ties at the Center for Animal Resources and Comparative Medicine
CNS-2 maintains the IL-4 locus of naive T cells in a at Harvard Medical School. NFAT1/, STAT6/, and c-Maf/ mice
have been described previously (Xanthoudakis et al., 1996; Kaplanpoised state, ready for the widespread changes in chro-
et al., 1996; Kim et al., 1999). STAT6/ mice were a gift from Dr.matin structure that accompany Th2 differentiation (Avni
Michael Grusby, and c-Maf/ mice were a gift from Dr. Laurieand Rao, 2000). However, this scenario is ruled out by
Glimcher. NFAT1/ mice on a mixed C57BL/6-129 backgroundour finding that the V/VA deletion does not interfere with were backcrossed to C57BL/6 for five generations, and C57BL/6
formation of the other DH sites in the IL-4 gene. Instead, mice were used as wild-type controls. BMMC from BALB/c mice was
the deletion seems to interfere with high level IL-4 ex- used as controls for both the STAT6/ and c-Maf/ experiments.
pression as described above, suggesting that the V/VA
BMMC Generation and Stimulationregion might orchestrate demethylation in other regions
Mice were sacrificed at 8–12 weeks of age, and bone marrow wasof the IL-4 gene. We are currently testing this possibility.
flushed from the femurs and tibias of each mouse with Razin medium
(RPMI 1640-BioWhittaker, supplemented with 10% fetal bovine se-
Overall Aspects rum, 2 mM glutamine, 50 U/ml penicillin, 50 g/ml streptomycin,
It is striking that the V/VA deletion, which includes CNS-2, nonessential amino acids, and 5 mM HEPES). Cells were resus-
affects IL-4 transcription in both mast cells and Th2 pended at approximately 4–5 	 105 cells/ml in 50% Razin me-
dium:50% WEHI-3 (ATCC) conditioned medium as a source of IL-3.cells. Previous work had suggested that these two cell
Cells were cultured in 50% WEHI-3 media for at least 4 weeks beforetypes use different regulatory elements to control IL-4
analysis, at which time the percentage of mast cells in the culturetranscription. An intronic enhancer was shown to bind
was 
99% as assessed by staining with toluidine blue.
mast cell-specific transcription factors and regulate the For stimulation, BMMC were resuspended in Razin medium at
accessibility and methylation status of the IL-4 gene in 10	 106 cells/ml. Cells were sensitized in 3 g/ml anti-dinitrophenol
mast cells (Henkel et al., 1992). Conversely, CNS-1, a (DNP) rat IgE (Zymed) for 1 hr at 37C. After removal of the cells
from IgE-containing medium, FcRI-bound IgE was then crosslinkedhighly conserved sequence in the intergenic region be-
for the indicated times with mouse anti-rat IgG F(ab)2 fragmentstween the IL-4 and IL-13 loci (Loots et al., 2000; Mohrs
(Jackson Immunoresearch Laboratories) at 25 g/ml.et al., 2001) was shown to function selectively in Th2
cells, since its deletion had no effect on IL-4 expression
DNase I Hypersensitivity
by mast cells. This scenario, in which regulation of a DNase I hypersensitivity of the IL-4 locus was analyzed as previously
single gene in two different cell types occurs through described (Agarwal and Rao, 1998). Southern blotting of BamHI-
utilization of different cis elements, has also been ob- digested DNA was performed using the 5 and 3 IL-4 probes (Agar-
wal and Rao, 1998).served for the CD8/ locus; in this case, different DH
clusters control CD8 expression in mature T cells and
Gene Targeting and Generation of V/VA KO Miceintraepithelial lymphocytes (IELs) (Hostert et al., 1997;
The targeting construct was created in pLNTK (Gorman et al., 1996),Ellmeier et al., 1998). Our results highlight an alternate
which contains a PGK-neor cassette for positive selection and an
mechanism to modulate gene expression, in which the HSV-tk gene for negative selection of random integration events.
same regulatory elements bind distinct but related tran- The neor cassette is flanked by loxp sites, enabling Cre-mediated
scription factors in different cell types (Weiss and deletion of the introduced selection cassette. The construct con-
tained as its 5 arm a 1.8 kb HindIII/HindIII fragment and as its 3Brown, 2001).
arm a 1.8 kb AvrII/HindIII fragment, for deletion of 3.7 kb encom-The V/VA deletion also has variable, less striking ef-
passing DH sites V and VA. The construct was electroporated intofects on expression of the linked genes IL-5 and IL-13.
TC1 ES cells, and cells were selected with G418 and gancyclovir.These results may be compared with previous work in For Cre deletion, targeted ES cells were electroporated with the pMC-
which deletion of CNS-1 caused a global decrease in CreN expression vector, and individual colonies were screened by
expression of IL-4, IL-5, and IL-13 by Th2 cells but had Southern analysis (Agarwal and Rao, 1998) for successful and com-
little effect on cytokine production by mast cells (Mohrs plete deletion. Positive colonies were subcloned, expanded, and
injected into C57BL/6 blastocysts for germline transmission. Miceet al., 2001). Why might the CNS-1 and V/VA deletions
were bred to homozygosity on the C57BL/6 background.have different effects on cytokine production by Th2
cells and mast cells? The V/VA deletion is more complex T Cell Differentiation and Stimulation
since it eliminates two potentially important elements, Spleen and lymph nodes were isolated from V/VA KO and C57BL/
the VA enhancer and DH site V, which contains CNS-2. 6J mice (3–4 weeks old). CD4 T cells were purified using magnetic
Analogous to CNS-1, CNS-2 may in fact be a global beads (Dynal) according to the manufacturer’s instructions. Th2
regulator of cytokine production in Th2 cells and mast cells were differentiated ex vivo as previously described (Agarwal
et al., 2000; Agarwal and Rao, 1998).cells, but deleting it in conjunction with the site VA en-
For stimulation, differentiated Th2 cells (10–20 	 106 ) were resus-hancer may focus the effects of the combined deletion
pended in cytokine- and antibody-free medium at a concentrationon IL-4 expression, thereby rendering the effects on IL-5
of 1 	 106 /ml and stimulated for the indicated times with 20 nM
and IL-13 less prominent. This hypothesis may be tested phorbol myristate acetate (PMA) and 2 M ionomycin as previously
by examining the individual effects of site VA and CNS-2 described (Agarwal et al., 2000; Agarwal and Rao, 1998). Where
deletions and by combining the CNS-2 deletion with plate-bound anti-CD3/anti-CD28 was used to stimulate Th2 cells,
plates were coated for 2 hr at 37C with 0.3 mg/ml goat anti-hamsterdeletion of CNS-1. If CNS-1 and CNS-2 indeed have
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antibody (Sigma) in PBS. Plates were then rinsed one time with permeabilized at room temperature for 10 min. Cells were then pel-
leted and resuspended in Fc block at 5 g/ml in saponin buffer forPBS before the addition of cells. Cells were washed in PBS and
resuspended in media containing 1 g/ml each of anti-CD3 and 5 min at room temperature to block binding of antibodies to the
FcIII/II receptors. Anti-IL-4-PE staining antibody (BD Pharmingen)anti-CD28 (BD Pharmingen) and added to the coated flasks for the
indicated times. was then added at 5 g/ml in saponin buffer and incubated at room
temperature in the dark for 20 min. Cells were washed twice with
saponin buffer, washed twice with PBS/1% BSA, resuspended inRNase Protection Assays (RPA)
PBS, and placed on ice until analysis. Flow cytometry analysis wasTotal RNA was isolated from cells using Ultraspec (Biotecx). RPA
performed on 50,000 events per sample on the FacsCalibur (Bectonanalysis was performed on 2–5 g of total RNA per time point using
Dickinson) using Cell Quest software.the Riboquant Kit (BD Pharmingen) according to the manufacturer’s
instructions. The mCK-1 and mCK-1b template sets are identical
RT-PCR Analysis of KIF3A Expressionexcept for the inclusion of an IL-6 probe in mCK-1 and an IL-3 probe
RT-PCR on RNA isolated from Th1 cells, Th2 cells, and BMMC wasin mCK-1b. The mCK-3 template set contains a probe for TNF-
performed for KIF3A expression with the Superscript One-Step KitmRNA. Bands in RPAs that corresponded to cytokine transcripts
(Life Technologies) according to the manufacturer’s instructions us-were quantified through use of the Phosphorimager and Image
ing the following primers: KIF3A forward, 5-TTTGCATATGGACAQuant program (Molecular Dynamics). Cytokine mRNA bands were
GACTGGG-3; KIF3A reverse, 5-GACCCAGCCAGATCCACAA-3.normalized to the corresponding L32 mRNA standard bands in each
lane, and relative intensity values were plotted.
Acknowledgments
FcRI and c-Kit Staining of BMMCs
We thank Laurie Davidson for her help in performing blastocystApproximately 0.5–2 	 106 WT, V/VA KO, and NFAT1/ BMMCs
injections; H. Katz, D. Joyal, and J. Lu-Kuo for kindly sharing theirwere washed twice with PBS/1% fetal bovine serum (FBS) and then
expertise in setting up BMMC cultures; L. Glimcher for providingincubated at 4C with 5g/ml anti-CD16/anti-CD32 (2.4G2, BD Phar-
c-Maf/ mice; M. Grusby for providing STAT6/ mice; and T.K.mingen) in PBS to block binding of antibodies to the FcIII/II recep-
Blackwell for valuable discussions and critical reading of the manu-tors (Fc block). All remaining steps were carried out at 4C. Mouse
script. This work was supported by NIH grants CA42471 and AI44432anti-DNP IgE (Sigma) was then added to the cells at 20 g/ml to
(to A.R.) and in part by NIH grants AI20047 and AI35714 (to F.W.A.).saturate the FcRI for 50 min. During the last 25 min of the incubation,
S.A. was supported by a Howard Hughes Medical Institute Predoc-biotinylated anti-c-Kit antibody (BD Pharmingen) at 15 g/ml was
toral Fellowship. D.C.S. and S.A. are Ryan Foundation Fellows.added (none was added for background control). Cells were washed
C.H.B. was a fellow of the Irvington Institute for Immunological Re-twice with PBS/1% FBS and resuspended in Fc block. Ten g/ml
search.of anti-IgE-FITC (fluorescein isothiocyanate) or 10 g/ml of anti-
IgG1-FITC as a background control and 2 g/ml streptavidin-PE
Received: December 4, 2001(phycoerythrin) (BD Pharmingen) were added to the cells which were
Revised: May 24, 2002incubated in the dark for 30 min. Cells were then washed twice with
PBS/1% FBS and resuspended in PBS, and 50,000 events were
Referencesanalyzed by flow cytometry using the FacsCalibur (Becton Dickin-
son) and Cell Quest software.
Agarwal, S., and Rao, A. (1998). Modulation of chromatin structure
regulates cytokine gene expression during T cell differentiation. Im-Antisera and Western Blotting
munity 9, 765–775.For anti-NFAT Western blots, wild-type and NFAT1-deficient BMMC
Agarwal, S., Avni, O., and Rao, A. (2000). Cell-type-restricted bindingwere pretreated with 1 mM cyclosporin A for 30 min to prevent
of the transcription factor NFAT to a distal IL-4 enhancer in vivo.dephosphorylation of NFAT or other phosphoproteins during cell
Immunity 12, 643–652.lysis. Whole-cell extracts were prepared from Th2 cells and BMMC
by resuspending cells in 2	 RSB (40 mM Tris-HCl [pH 7.8], 10 mM Avni, O., and Rao, A. (2000). T cell differentiation: a mechanistic
EDTA, 60 mM sodium pyrophosphate, 0.2 g/ml aprotinin, 50 M view. Curr. Opin. Immunol. 12, 654–659.
leupeptin, and 0.4 mM PMSF). An equal volume of 10% SDS was Brown, M.A., and Hural, J. (1997). Functions of IL-4 and control of
added, and the samples were boiled. Lysates were run on polyacryl- its expression. Crit. Rev. Immunol. 17, 1–32.
amide gels as indicated in the figure legends and transferred to
Ellmeier, W., Sunshine, M.J., Losos, K., and Littman, D.R. (1998).nitrocellulose. Lysates of HEK293 cells transfected with NFAT ex-
Multiple developmental stage-specific enhancers regulate CD8 ex-pression constructs were a gift from Dr. Jose Aramburu. Antibodies
pression in developing thymocytes and in thymus-independent Tused in Western blotting were as follows: anti-GATA-3, HG3-31
cells. Immunity 9, 485–496.(Santa Cruz Biotechnology); anti-NFAT1, anti-67.1 (Ho et al., 1994;
Frazer, K.A., Ueda, Y., Zhu, Y., Gifford, V.R., Garofalo, M.R., Mohan-Shaw et al., 1995); anti-NFAT2, 7A6 (Affinity Bioreagents). Anti-
das, N., Martin, C.H., Palazzolo, M.J., Cheng, J.F., and Rubin, E.M.NFAT4 (Lyakh et al., 1997) was kindly provided by Dr. Nancy Rice.
(1997). Computational and biological analysis of 680 kb of DNA
sequence from the human 5q31 cytokine gene cluster region. Ge-ELISA Analysis of Cytokine Production
nome Res. 7, 495–512.Th2 cells were stimulated as described above. At the indicated
Galli, S.J. (1993). New concepts about the mast cell. N. Engl. J. Med.times, supernatants were collected from the cells and serially diluted
328, 257–265.to obtain results within the linear range of the assay. Capture and
detection antibodies were used at the following concentrations: Galli, S.J., and Hammel, I. (1994). Mast cell and basophil develop-
anti-IL-4 (BD Pharmingen), 1 g/ml; anti-IL-5 (BD Pharmingen), 2 ment. Curr. Opin. Hematol. 1, 33–39.
g/ml; anti-IL-10 (R&D Systems), 2 g/ml capture, 400 ng/ml detec- Galli, S.J., Dvorak, A.M., Marcum, J.A., Ishizaka, T., Nabel, G., Der
tion; anti-IL-13 (R&D Systems), 3 g/ml capture, 200 ng/ml de- Simonian, H., Pyne, K., Goldin, J.M., Rosenberg, R.D., Cantor, H.,
tection. and Dvorak, H.F. (1982). Mast cell clones: a model for the analysis
of cellular maturation. J. Cell Biol. 95, 435–444.
Intracellular Cytokine Staining
Glimcher, L.H., and Murphy, K.M. (2000). Lineage commitment in
Th2 cells were stimulated as described above. During the last 2 hr
the immune system: the T helper lymphocyte grows up. Genes Dev.
of stimulation, 10 g/ml brefeldin A (Sigma) was added to the cells.
14, 1693–1711.
Cells were collected and washed one time in PBS/1% BSA and one
Gorman, J.R., van der Stoep, N., Monroe, R., Cogne, M., Davidson,time with PBS alone, after which they were resuspended in 500 l
L., and Alt, F.W. (1996). The Ig() enhancer influences the ratio of4% paraformaldehyde in PBS and fixed at room temperature for 10
Ig() versus Ig() B lymphocytes. Immunity 5, 241–252.min. Fixing was followed by one wash in PBS/1% BSA. After wash-
ing, cells were resuspended in 0.5% saponin in PBS/1% BSA and Henkel, G., and Brown, M.A. (1994). PU.1 and GATA: components
Immunity
50
of a mast cell-specific interleukin 4 intronic enhancer. Proc. Natl. (1985). Fate of bone marrow-derived cultured mast cells after intra-
cutaneous, intraperitoneal, and intravenous transfer into geneticallyAcad. Sci. USA 91, 7737–7741.
mast cell-deficient W/Wv mice. Evidence that cultured mast cellsHenkel, G., Weiss, D.L., McCoy, R., Deloughery, T., Tara, D., and
can give rise to both connective tissue type and mucosal mast cells.Brown, M.A. (1992). A DNase I-hypersensitive site in the second
J. Exp. Med. 162, 1025–1043.intron of the murine IL-4 gene defines a mast cell-specific enhancer.
J. Immunol. 149, 3239–3246. O’Garra, A. (1998). Cytokines induce the development of functionally
heterogeneous T helper cell subsets. Immunity 8, 275–283.Ho, A.M., Jain, J., Rao, A., and Hogan, P.G. (1994). Expression of
the transcription factor NFATp in a neuronal cell line and in the O’Garra, A., and Arai, N. (2000). The molecular basis of T helper 1
and T helper 2 cell differentiation. Trends Cell Biol. 10, 542–550.murine nervous system. J. Biol. Chem. 269, 28181–28186.
Hodge, M.R., Ranger, A.M., de la Brousse, F.C., Hoey, T., Grusby, Peng, S.L., Gerth, A.J., Ranger, A.M., and Glimcher, L.H. (2001).
NFATc1 and NFATc2 together control both T and B cell activationM.J., and Glimcher, L.H. (1996). Hyperproliferation and dysregulation
of IL-4 expression in NF-ATp-deficient mice. Immunity 4, 397–405. and differentiation. Immunity 14, 13–20.
Romagnani, S. (1994). Lymphokine production by human T cells inHostert, A., Tolaini, M., Roderick, K., Harker, N., Norton, T., and
Kioussis, D. (1997). A region in the CD8 gene locus that directs disease states. Annu. Rev. Immunol. 12, 227–257.
expression to the mature CD8 T cell subset in transgenic mice. Seder, R.A., Paul, W.E., Davis, M.M., and Fazekas de St Groth, B.
Immunity 7, 525–536. (1992). The presence of interleukin 4 during in vitro priming deter-
mines the lymphokine-producing potential of CD4 T cells from THural, J.A., Kwan, M., Henkel, G., Hock, M.B., and Brown, M.A.
(2000). An intron transcriptional enhancer element regulates IL-4 cell receptor transgenic mice. J. Exp. Med. 176, 1091–1098.
gene locus accessibility in mast cells. J. Immunol. 165, 3239–3249. Shaw, K.T., Ho, A.M., Raghavan, A., Kim, J., Jain, J., Park, J.,
Sharma, S., Rao, A., and Hogan, P.G. (1995). ImmunosuppressiveKaplan, M.H., Schindler, U., Smiley, S.T., and Grusby, M.J. (1996).
Stat6 is required for mediating responses to IL-4 and for develop- drugs prevent a rapid dephosphorylation of transcription factor
NFAT1 in stimulated immune cells. Proc. Natl. Acad. Sci. USA 92,ment of Th2 cells. Immunity 4, 313–319.
11205–11209.Kiani, A., Viola, J.P., Lichtman, A.H., and Rao, A. (1997). Downregula-
tion of IL-4 gene transcription and control of Th2 cell differentiation Sher, A., and Coffman, R.L. (1992). Regulation of immunity to para-
sites by T cells and T cell-derived cytokines. Annu. Rev. Immunol.by a mechanism involving NFAT1. Immunity 7, 849–860.
10, 385–409.Kim, J.I., Ho, I.C., Grusby, M.J., and Glimcher, L.H. (1999). The tran-
scription factor c-Maf controls the production of interleukin-4 but Sherman, M.A., Nachman, T.Y., and Brown, M.A. (1999a). Cutting
edge: IL-4 production by mast cells does not require c-maf. J. Immu-not other Th2 cytokines. Immunity 10, 745–751.
nol. 163, 1733–1736.Kitamura, Y. (1989). Heterogeneity of mast cells and phenotypic
change between subpopulations. Annu. Rev. Immunol. 7, 59–76. Sherman, M.A., Secor, V.H., Lee, S.K., Lopez, R.D., and Brown, M.A.
(1999b). STAT6-independent production of IL-4 by mast cells. Eur.Kondo, S., Sato-Yoshitake, R., Noda, Y., Aizawa, H., Nakata, T.,
J. Immunol. 29, 1235–1242.Matsuura, Y., and Hirokawa, N. (1994). KIF3A is a new microtubule-
based anterograde motor in the nerve axon. J. Cell Biol. 125, 1095– Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashi-
wamura, S., Nakanishi, K., Yoshida, N., Kishimoto, T., and Akira, S.1107.
(1996). Essential role of Stat6 in IL-4 signalling. Nature 380, 627–630.Lee, G.R., Fields, P.E., and Flavell, R.A. (2001). Regulation of IL-4
gene expression by distal regulatory elements and GATA-3 at the Takemoto, N., Koyano-Nakagawa, N., Yokota, T., Arai, N., Miyatake,
S., and Arai, K. (1998). Th2-specific DNase I-hypersensitive siteschromatin level. Immunity 14, 447–459.
in the murine IL-13 and IL-4 intergenic region. Int. Immunol. 10,Lee, D.U., Agarwal, S., and Rao, A. (2002). Th2 lineage commitment
1981–1985.and efficient IL-4 production involves extended demethylation of
the IL-4 gene. Immunity 16, 649–660. Wardlaw, A.J., Moqbel, R., and Kay, A.B. (1995). Eosinophils: biology
and role in disease. Adv. Immunol. 60, 151–266.Loots, G.G., Locksley, R.M., Blankespoor, C.M., Wang, Z.E., Miller,
W., Rubin, E.M., and Frazer, K.A. (2000). Identification of a coordi- Weiss, M.J., and Orkin, S.H. (1995). GATA transcription factors: key
regulators of hematopoiesis. Exp. Hematol. 23, 99–107.nate regulator of interleukins 4, 13, and 5 by cross-species sequence
comparisons. Science 288, 136–140. Weiss, D.L., and Brown, M.A. (2001). Regulation of IL-4 production
in mast cells: a paradigm for cell-type-specific gene expression.Lyakh, L., Ghosh, P., and Rice, N.R. (1997). Expression of NFAT-
family proteins in normal human T cells. Mol. Cell. Biol. 17, 2475– Immunol. Rev. 179, 35–47.
2484. Xanthoudakis, S., Viola, J.P., Shaw, K.T., Luo, C., Wallace, J.D.,
Bozza, P.T., Luk, D.C., Curran, T., and Rao, A. (1996). An enhancedMartin, D.I., Zon, L.I., Mutter, G., and Orkin, S.H. (1990). Expression
of an erythroid transcription factor in megakaryocytic and mast cell immune response in mice lacking the transcription factor NFAT1.
Science 272, 892–895.lineages. Nature 344, 444–447.
Mekori, Y.A., and Metcalfe, D.D. (2000). Mast cells in innate immu- Xu, X., Sun, Y.L., and Hoey, T. (1996). Cooperative DNA binding
and sequence-selective recognition conferred by the STAT amino-nity. Immunol. Rev. 173, 131–140.
terminal domain. Science 273, 794–797.Mohrs, M., Blankespoor, C.M., Wang, Z.E., Loots, G.G., Afzal, V.,
Hadeiba, H., Shinkai, K., Rubin, E.M., and Locksley, R.M. (2001). Zhang, D.H., Yang, L., Cohn, L., Parkyn, L., Homer, R., Ray, P., and
Ray, A. (1999). Inhibition of allergic inflammation in a murine modelDeletion of a coordinate regulator of type 2 cytokine expression in
mice. Nat. Immunol. 2, 842–847. of asthma by expression of a dominant-negative mutant of GATA-3.
Immunity 11, 473–482.Mosmann, T.R., and Coffman, R.L. (1989). TH1 and TH2 cells: differ-
ent patterns of lymphokine secretion lead to different functional Zheng, W., and Flavell, R.A. (1997). The transcription factor GATA-3
is necessary and sufficient for Th2 cytokine gene expression in CD4properties. Annu. Rev. Immunol. 7, 145–173.
T cells. Cell 89, 587–596.Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., and Coff-
man, R.L. (1986). Two types of murine helper T cell clone. I. Definition Zon, L.I., Gurish, M.F., Stevens, R.L., Mather, C., Reynolds, D.S.,
Austen, K.F., and Orkin, S.H. (1991). GATA-binding transcriptionaccording to profiles of lymphokine activities and secreted proteins.
J. Immunol. 136, 2348–2357. factors in mast cells regulate the promoter of the mast cell carboxy-
peptidase A gene. J. Biol. Chem. 266, 22948–22953.Murphy, K.M., Ouyang, W., Farrar, J.D., Yang, J., Ranganath, S.,
Asnagli, H., Afkarian, M., and Murphy, T.L. (2000). Signaling and Zurawski, G., and de Vries, J.E. (1994). Interleukin 13, an interleukin
4-like cytokine that acts on monocytes and B cells, but not on Ttranscription in T helper development. Annu. Rev. Immunol. 18,
451–494. cells. Immunol. Today 15, 19–26.
Nakano, T., Sonoda, T., Hayashi, C., Yamatodani, A., Kanayama, Y.,
Yamamura, T., Asai, H., Yonezawa, T., Kitamura, Y., and Galli, S.J.
